Table 6.

Summary of the main results regarding the use of anti-inflammatory agents in patients with Chagas cardiomyopathy

Study	Study design	Intervention	Outcome
Sousa et al. (2008)	Prospective observational cohort	(1) Warfarin (INR 2-3) for 14 months; (2) acetylsalicylic acid (ASA) (200 mg/day) for 22±21 months.	Prophylaxis recommendation: Warfarin for patients where the EC risk exceeds the risk of a major bleeding; Bleeding risk similar to EC risk of using warfarin or ASA according to individual choice; Low risk for EC use of ASA or no therapy.
Rassi et al. (2002)	Case study-analytical observational	Nifurtimox (8 to 9mg kg day-1) for 60 days; and decreasing doses of betamethasone (9 – 1 mg day-1) for 60 days	There were no negative results of the serological tests and transient negativity was only occasionally found or the eventual outcome was inconclusive; Nine patients with xenodiagnostics documented therapeutic failure: onset of heart disease or worsening of pre-existent condition in four patients; Concomitant use of nifurtimox and betamethasone did not lead to progress in the etiological therapy of chronic Chagas disease.